Selumetinib for NF2-Related Schwannomatosis

NCT07707947 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Neurofibromatosis Type 2
NF2
NF2-related Schwannomatosis
Meningioma
Ependymoma
Vestibular Schwannoma

Interventions

DRUG: Selumetinib

Sponsor

Beijing Tiantan Hospital

Collaborators

[object Object]